Clicky

Cellectis S.A.(CLLS) News

Date Title
May 12 Cellectis Reports Financial Results for the First Quarter 2025
May 6 Cellectis to Report First Quarter Financial Results on May 12, 2025
Apr 25 3 European Penny Stocks With At Least €100M Market Cap
Apr 21 Cellectis SA (CLLS) Q4 2024 Earnings Call Highlights: Strategic Collaborations and Financial ...
Mar 13 Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2024 and Provides a Business Update
Feb 24 Cellectis Presents ‘Smart CAR T’ Strategy to Enhance Efficacy Against Solid Tumors at AACR-IO 2025
Dec 29 Analysts Predict 400% Upside Potential for This Penny Stock
Aug 26 Cellectis Publishes a Molecular Therapy Article on a SMART DUAL CAR T-cell Approach for Treating Recalcitrant Solid Tumors
Aug 7 Cellectis Appoints Dr. Adrian Kilcoyne as Chief Medical Officer
Aug 6 Cellectis Provides Financial Results for the Second Quarter 2024
Jul 25 FDA Grants Orphan Drug and Rare Pediatric Disease Designation Status to Cellectis’ UCART22 product candidate for Acute Lymphoblastic Leukemia (ALL) Treatment
Jun 12 Cellectis Unveils a Non-Viral Gene Therapy Approach for Sickle Cell Disease in Nature Communications
May 7 AstraZeneca concludes equity investment in Cellectis
May 6 AstraZeneca ups stake in Cellectis in latest cell therapy bet
May 6 Cellectis Announces Completion of the Additional Equity Investment by AstraZeneca
May 2 Cellectis Appoints Arthur Stril as Interim Chief Financial Officer
Apr 29 Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2023
Apr 22 Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCs
Apr 10 Cellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of Inborn Metabolic Diseases by Edited HSPCs
Apr 8 Cellectis Announces Two Poster Presentations on Novel TALEN® Editing Process for Gene Correction and Gene Insertion in HSPCs at the ASGCT Annual Meeting